Hereditary Breast Cancer Syndromes

  • Alfredo A. Santillan
  • Jeffrey M. Farma
  • Ramona Hagmaier
  • Charles E. Cox
  • Adam I. Riker


Breast cancer represents a major public health problem in the world. According to the GLOBOCAN database, breast cancer is the second most common cancer in the world and the most common cancer among women, accounting for an estimated 1,152,161 new cases each year and 411,093 cancer deaths per year (Fig. 4.1) [1]. In the United States, breast cancer is the second leading cause of cancer death among women after lung cancer [2]. Recent trends in the incidence of female breast cancer have shown a sharp decrease during the period of 1999–2003. This can be partly explained by the increased utilization of screening mammography, better technologies that increase the sensitivity of detection suspicious abnormalities, and an overall reduction in the use of hormone replacement therapy (Fig. 4.2) [3]. Despite this recent decrease in breast cancer incidence, it is estimated that in the year 2007, more than 178,480 women will be diagnosed with breast cancer in the United States, with approximately 40,460 women dying from this disease. Of these, about 5–10% of the total breast cancer burden will be hereditary, having affected approximately 8,924–17,848 patients during 2007 [2].


Breast Cancer Ovarian Cancer Breast Cancer Risk Mutation Carrier BRCA Mutation 


  1. 1.
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137–50.PubMedCrossRefGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.PubMedCrossRefGoogle Scholar
  3. 3.
    Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007;9:R28.PubMedCrossRefGoogle Scholar
  4. 4.
    Antoniou AC, Easton DF. Models of genetic susceptibility to breast cancer. Oncogene 2006;25:5898–905.PubMedCrossRefGoogle Scholar
  5. 5.
    Colditz GA, Willett WC, Hunter DJ, et al. Family history, age, and risk of breast cancer. Prospective data from the Nurses’ Health Study. JAMA 1993;270:338–43.PubMedCrossRefGoogle Scholar
  6. 6.
    Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. JAMA 1993;270:1563–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Claus EB, Risch NJ, Thompson WD. Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol 1990;131:961–72.PubMedGoogle Scholar
  8. 8.
    Anderson DE, Badzioch MD. Combined effect of family history and reproductive factors on breast cancer risk. Cancer 1989;63:349–53.PubMedCrossRefGoogle Scholar
  9. 9.
    Narod SA. Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer 2002;2:113–23.PubMedCrossRefGoogle Scholar
  10. 10.
    Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol 2005;23:8629–35.PubMedCrossRefGoogle Scholar
  11. 11.
    Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94:1365–72.PubMedCrossRefGoogle Scholar
  12. 12.
    Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993;52:678–701.PubMedGoogle Scholar
  13. 13.
    Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117–30.PubMedCrossRefGoogle Scholar
  14. 14.
    Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 2000;83:1301–8.CrossRefGoogle Scholar
  15. 15.
    Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Warner E, Foulkes W, Goodwin P, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999;91:1241–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Thorlacius S, Struewing JP, Hartge P, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998;352:1337–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329–33.PubMedCrossRefGoogle Scholar
  19. 19.
    Martin AM, Weber BL. Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst 2000;92:1126–35.PubMedCrossRefGoogle Scholar
  20. 20.
    Kennedy RD, Quinn JE, Johnston PG, Harkin DP. BRCA1: mechanisms of inactivation and implications for management of patients. Lancet 2002;360:1007–14.PubMedCrossRefGoogle Scholar
  21. 21.
    Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265–71.PubMedGoogle Scholar
  22. 22.
    Struewing JP, Tarone RE, Brody LC, Li FP, Boice JD Jr. BRCA1 mutations in young women with breast cancer. Lancet 1996;347:1493.PubMedCrossRefGoogle Scholar
  23. 23.
    Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990;250:1684–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66–71.PubMedCrossRefGoogle Scholar
  25. 25.
    Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006;295:1379–88.PubMedCrossRefGoogle Scholar
  26. 26.
    Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994;266:120–2.PubMedCrossRefGoogle Scholar
  27. 27.
    Castilla LH, Couch FJ, Erdos MR, et al. Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat Genet 1994;8:387–91.PubMedCrossRefGoogle Scholar
  28. 28.
    Friedman LS, Ostermeyer EA, Szabo CI, et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994;8:399–404.PubMedCrossRefGoogle Scholar
  29. 29.
    Simard J, Tonin P, Durocher F, et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 1994;8:392–8.PubMedCrossRefGoogle Scholar
  30. 30.
    FitzGerald MG, MacDonald DJ, Krainer M, et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996;334:143–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Muto MG, Cramer DW, Tangir J, Berkowitz R, Mok S. Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls. Cancer Res 1996;56:1250–2.PubMedGoogle Scholar
  32. 32.
    Abeliovich D, Kaduri L, Lerer I, et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997;60:505–14.PubMedGoogle Scholar
  33. 33.
    Couch FJ, Weber BL. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core. Hum Mutat 1996;8:8–18.PubMedCrossRefGoogle Scholar
  34. 34.
    Tonin P, Serova O, Lenoir G, et al. BRCA1 mutations in Ashkenazi Jewish women. Am J Hum Genet 1995;57:189.PubMedGoogle Scholar
  35. 35.
    Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Berman DB, Wagner-Costalas J, Schultz DC, Lynch HT, Daly M, Godwin AK. Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15 185delAG-mutation kindreds. Am J Hum Genet 1996;58:1166–76.PubMedGoogle Scholar
  37. 37.
    Offit K, Gilewski T, McGuire P, et al. Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet 1996;347:1643–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Shen SX, Weaver Z, Xu X, et al. A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene 1998;17: 3115–24.PubMedCrossRefGoogle Scholar
  39. 39.
    Xu X, Qiao W, Linke SP, et al. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet 2001;28:266–71.PubMedCrossRefGoogle Scholar
  40. 40.
    Ohta T, Fukuda M. Ubiquitin and breast cancer. Oncogene 2004;23:2079–88.PubMedCrossRefGoogle Scholar
  41. 41.
    Pavelic K, Gall-Troselj K. Recent advances in molecular genetics of breast cancer. J Mol Med 2001;79:566–73.PubMedCrossRefGoogle Scholar
  42. 42.
    Zheng L, Li S, Boyer TG, Lee WH. Lessons learned from BRCA1 and BRCA2. Oncogene 2000;19:6159–75.PubMedCrossRefGoogle Scholar
  43. 43.
    Xu X, Weaver Z, Linke SP, et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 1999;3:389–95.PubMedCrossRefGoogle Scholar
  44. 44.
    Anderson SF, Schlegel BP, Nakajima T, Wolpin ES, Parvin JD. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat Genet 1998;19:254–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Scully R, Anderson SF, Chao DM, et al. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci U S A 1997;94:5605–10.PubMedCrossRefGoogle Scholar
  46. 46.
    Scully R, Chen J, Plug A, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997;88:265–75.PubMedCrossRefGoogle Scholar
  47. 47.
    Chen JJ, Silver D, Cantor S, Livingston DM, Scully R. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res 1999;59:1752s–6s.PubMedGoogle Scholar
  48. 48.
    Hsu LC, White RL. BRCA1 is associated with the centrosome during mitosis. Proc Natl Acad Sci U S A 1998;95:12983–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Carroll PE, Okuda M, Horn HF, et al. Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene 1999;18:1935–44.PubMedCrossRefGoogle Scholar
  50. 50.
    Shao N, Chai YL, Shyam E, Reddy P, Rao VN. Induction of apoptosis by the tumor suppressor protein BRCA1. Oncogene 1996;13:1–7.PubMedGoogle Scholar
  51. 51.
    Harkin DP, Bean JM, Miklos D, et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 1999;97:575–86.PubMedCrossRefGoogle Scholar
  52. 52.
    Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 1998;281:1009–12.PubMedCrossRefGoogle Scholar
  53. 53.
    Abbott DW, Thompson ME, Robinson-Benion C, Tomlinson G, Jensen RA, Holt JT. BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J Biol Chem 1999;274:18808–12.PubMedCrossRefGoogle Scholar
  54. 54.
    Deng CX, Scott F. Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation. Oncogene 2000;19:1059–64.PubMedCrossRefGoogle Scholar
  55. 55.
    Deng CX, Brodie SG. Roles of BRCA1 and its interacting proteins. Bioessays 2000;22:728–37.PubMedCrossRefGoogle Scholar
  56. 56.
    Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171–82.PubMedCrossRefGoogle Scholar
  57. 57.
    Deng CX. Tumor formation in Brca1 conditional mutant mice. Environ Mol Mutagen 2002;39:171–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Brodie SG, Deng CX. BRCA1-associated tumorigenesis: what have we learned from knockout mice? Trends Genet 2001;17:S18–22.PubMedCrossRefGoogle Scholar
  59. 59.
    Deng CX. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res 2006;34:1416–26.PubMedCrossRefGoogle Scholar
  60. 60.
    Shamoo Y. Structural insights into BRCA2 function. Curr Opin Struct Biol 2003;13:206–11.PubMedCrossRefGoogle Scholar
  61. 61.
    Vaughn JP, Cirisano FD, Huper G, et al. Cell cycle control of BRCA2. Cancer Res 1996;56:4590–4.PubMedGoogle Scholar
  62. 62.
    Phelan CM, Lancaster JM, Tonin P, et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet 1996;13:120–2.PubMedCrossRefGoogle Scholar
  63. 63.
    Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789–92.PubMedCrossRefGoogle Scholar
  64. 64.
    Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996;12:333–7.PubMedCrossRefGoogle Scholar
  65. 65.
    Couch FJ, Farid LM, DeShano ML, et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 1996;13:123–5.PubMedCrossRefGoogle Scholar
  66. 66.
    Neuhausen S, Gilewski T, Norton L, et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 1996;13:126–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Lancaster JM, Wooster R, Mangion J, et al. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 1996;13:238–40.PubMedCrossRefGoogle Scholar
  68. 68.
    Miki Y, Katagiri T, Kasumi F, Yoshimoto T, Nakamura Y. Mutation analysis in the BRCA2 gene in primary breast cancers. Nat Genet 1996;13:245–7.PubMedCrossRefGoogle Scholar
  69. 69.
    Takahashi H, Chiu HC, Bandera CA, et al. Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res 1996;56:2738–41.PubMedGoogle Scholar
  70. 70.
    Agnarsson BA, Jonasson JG, Bjornsdottir IB, Barkardottir RB, Egilsson V, Sigurdsson H. Inherited BRCA2 mutation associated with high grade breast cancer. Breast Cancer Res Treat 1998;47:121–7.PubMedCrossRefGoogle Scholar
  71. 71.
    Schubert EL, Lee MK, Mefford HC, et al. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet 1997;60:1031–40.PubMedGoogle Scholar
  72. 72.
    Inoue R, Ushijima T, Fukutomi T, et al. BRCA2 germline mutations in Japanese breast cancer families. Int J Cancer 1997;74:199–204.PubMedCrossRefGoogle Scholar
  73. 73.
    Oddoux C, Struewing JP, Clayton CM, et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996;14:188–90.PubMedCrossRefGoogle Scholar
  74. 74.
    Johannesdottir G, Gudmundsson J, Bergthorsson JT, et al. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res 1996;56:3663–5.PubMedGoogle Scholar
  75. 75.
    Vehmanen P, Friedman LS, Eerola H, et al. A low proportion of BRCA2 mutations in Finnish breast cancer families. Am J Hum Genet 1997;60:1050–8.PubMedGoogle Scholar
  76. 76.
    Szabo CI, King MC. Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997;60:1013–20.PubMedGoogle Scholar
  77. 77.
    Zheng L, Annab LA, Afshari CA, Lee WH, Boyer TG. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci U S A 2001;98:9587–92.PubMedCrossRefGoogle Scholar
  78. 78.
    Yang Q, Khoury MJ, Rodriguez C, Calle EE, Tatham LM, Flanders WD. Family history score as a predictor of breast cancer mortality: prospective data from the Cancer Prevention Study II, United States, 1982–1991. Am J Epidemiol 1998;147:652–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 1997;71:800–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996;77:2318–24.PubMedCrossRefGoogle Scholar
  81. 81.
    Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001;358:1389–99.Google Scholar
  82. 82.
    Beers NS, Kemeny A, Sherritt L, Palfrey JS. Variations in state-level definitions: children with special health care needs. Public Health Rep 2003;118:434–47.PubMedCrossRefGoogle Scholar
  83. 83.
    Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995;57:1457–62.PubMedGoogle Scholar
  84. 84.
    Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006;98:1694–706.PubMedCrossRefGoogle Scholar
  85. 85.
    Antoniou AC, Pharoah PD, McMullan G, et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 2002;86:76–83.PubMedCrossRefGoogle Scholar
  86. 86.
    Whittemore AS, Gong G, John EM, et al. Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites. Cancer Epidemiol Biomarkers Prev 2004;13:2078–83.PubMedGoogle Scholar
  87. 87.
    Tonin P, Weber B, Offit K, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996;2:1179–83.PubMedCrossRefGoogle Scholar
  88. 88.
    Verhoog LC, van den Ouweland AM, Berns E, et al. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. Eur J Cancer 2001;37:2082–90.PubMedCrossRefGoogle Scholar
  89. 89.
    Gorski B, Jakubowska A, Huzarski T, et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 2004;110:683–6.PubMedCrossRefGoogle Scholar
  90. 90.
    Dite GS, Jenkins MA, Southey MC, et al. Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. J Natl Cancer Inst 2003;95:448–57.PubMedCrossRefGoogle Scholar
  91. 91.
    Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T. The lifetime risk of developing breast cancer. J Natl Cancer Inst 1993;85:892–7.PubMedCrossRefGoogle Scholar
  92. 92.
    Rockhill B, Weinberg CR, Newman B. Population attributable fraction estimation for established breast cancer risk factors: considering the issues of high prevalence and unmodifiability. Am J Epidemiol 1998;147:826–33.PubMedCrossRefGoogle Scholar
  93. 93.
    Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN. Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst 1995;87:1681–5.PubMedCrossRefGoogle Scholar
  94. 94.
    Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879–86.PubMedCrossRefGoogle Scholar
  95. 95.
    Hildreth NG, Shore RE, Dvoretsky PM. The risk of breast cancer after irradiation of the thymus in infancy. N Engl J Med 1989;321:1281–4.PubMedCrossRefGoogle Scholar
  96. 96.
    Hunter DJ, Spiegelman D, Adami HO, et al. Cohort studies of fat intake and the risk of breast cancer-a pooled analysis. N Engl J Med 1996;334:356–61.PubMedCrossRefGoogle Scholar
  97. 97.
    Rosenberg L, Palmer JR, Rao RS, et al. Case-control study of oral contraceptive use and risk of breast cancer. Am J Epidemiol 1996;143:25–37.PubMedCrossRefGoogle Scholar
  98. 98.
    Michels KB, Willett WC. Does induced or spontaneous abortion affect the risk of breast cancer? Epidemiology 1996;7:521–8.PubMedCrossRefGoogle Scholar
  99. 99.
    Antoniou AC, Shenton A, Maher ER, et al. Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2006;8:R72.PubMedCrossRefGoogle Scholar
  100. 100.
    Andrieu N, Goldgar DE, Easton DF, et al. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst 2006;98:535–44.PubMedCrossRefGoogle Scholar
  101. 101.
    Chang-Claude J, Andrieu N, Rookus M, et al. Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 2007;16:740–6.PubMedCrossRefGoogle Scholar
  102. 102.
    Spiegelman D, Colditz GA, Hunter D, Hertzmark E. Validation of the Gail et al. model for predicting individual breast cancer risk. J Natl Cancer Inst 1994;86:600–7.PubMedCrossRefGoogle Scholar
  103. 103.
    Bondy ML, Lustbader ED, Halabi S, Ross E, Vogel VG. Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst 1994;86:620–5.PubMedCrossRefGoogle Scholar
  104. 104.
    Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999;91:1541–8.PubMedCrossRefGoogle Scholar
  105. 105.
    Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001;93:358–66.PubMedCrossRefGoogle Scholar
  106. 106.
    Decarli A, Calza S, Masala G, Specchia C, Palli D, Gail MH. Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European Prospective Investigation into Cancer and Nutrition cohort. J Natl Cancer Inst 2006;98:1686–93.PubMedCrossRefGoogle Scholar
  107. 107.
    Chen J, Pee D, Ayyagari R, et al. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 2006;98:1215–26.PubMedCrossRefGoogle Scholar
  108. 108.
    Barlow WE, White E, Ballard-Barbash R, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 2006;98:1204–14.PubMedCrossRefGoogle Scholar
  109. 109.
    Mitchell G, Antoniou AC, Warren R, et al. Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Res 2006;66:1866–72.PubMedCrossRefGoogle Scholar
  110. 110.
    Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994;73:643–51.PubMedCrossRefGoogle Scholar
  111. 111.
    Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57:75–89.PubMedCrossRefGoogle Scholar
  112. 112.
    Simon MS, Korczak JF, Yee CL, et al. Breast cancer risk estimates for relatives of white and African American women with breast cancer in the Women’s Contraceptive and Reproductive Experiences Study. J Clin Oncol 2006;24:2498–504.PubMedCrossRefGoogle Scholar
  113. 113.
    Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991;48:232–42.PubMedGoogle Scholar
  114. 114.
    Couch FJ, DeShano ML, Blackwood MA, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997;336:1409–15.PubMedCrossRefGoogle Scholar
  115. 115.
    Shattuck-Eidens D, Oliphant A, McClure M, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997;278:1242–50.PubMedCrossRefGoogle Scholar
  116. 116.
    Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 1997;89:227–38.PubMedCrossRefGoogle Scholar
  117. 117.
    Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998;62:145–58.PubMedCrossRefGoogle Scholar
  118. 118.
    Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 1999;64:963–70.PubMedCrossRefGoogle Scholar
  119. 119.
    Gilpin CA, Carson N, Hunter AG. A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. Clin Genet 2000;58:299–308.PubMedCrossRefGoogle Scholar
  120. 120.
    Vahteristo P, Eerola H, Tamminen A, Blomqvist C, Nevanlinna H. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer 2001;84:704–8.PubMedCrossRefGoogle Scholar
  121. 121.
    Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20:1480–90.PubMedCrossRefGoogle Scholar
  122. 122.
    Apicella C, Dowty JG, Dite GS, et al. Validation study of the LAMBDA model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women. Clin Genet 2007;72:87–97.PubMedCrossRefGoogle Scholar
  123. 123.
    de la Hoya M, Diez O, Perez-Segura P, et al. Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics. J Med Genet 2003;40:503–10.PubMedCrossRefGoogle Scholar
  124. 124.
    Evans DG, Eccles DM, Rahman N, et al. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 2004;41:474–80.PubMedCrossRefGoogle Scholar
  125. 125.
    Antoniou AC, Pharoah PP, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 2004;91:1580–90.PubMedGoogle Scholar
  126. 126.
    Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004;23:1111–30.PubMedCrossRefGoogle Scholar
  127. 127.
    Parmigiani G, Chen S, Iversen ES Jr.,et al.., Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med 2007;147:441–50.PubMedGoogle Scholar
  128. 128.
    Domchek SM, Eisen A, Calzone K, Stopfer J, Blackwood A, Weber BL. Application of breast cancer risk prediction models in clinical practice. J Clin Oncol 2003;21:593–601.PubMedCrossRefGoogle Scholar
  129. 129.
    Trepanier A, Ahrens M, McKinnon W, et al. Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. J Genet Couns 2004;13:83–114.PubMedCrossRefGoogle Scholar
  130. 130.
    American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003;21:2397–406.Google Scholar
  131. 131.
    Nanda R, Schumm LP, Cummings S, et al. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 2005;294:1925–33.PubMedCrossRefGoogle Scholar
  132. 132.
    Vogel KJ, Atchley DP, Erlichman J, et al. BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol 2007;25:4635–41.PubMedCrossRefGoogle Scholar
  133. 133.
    Berliner JL, Fay AM. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. J Genet Couns 2007;16:241–60.PubMedCrossRefGoogle Scholar
  134. 134.
    Weitzel JN, Lagos VI, Cullinane CA, et al. Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA 2007;297:2587–95.PubMedCrossRefGoogle Scholar
  135. 135.
    Braithwaite D, Emery J, Walter F, Prevost AT, Sutton S. Psychological impact of genetic counseling for familial cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2004;96:122–33.PubMedCrossRefGoogle Scholar
  136. 136.
    Lerman C, Narod S, Schulman K, et al. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA 1996;275:1885–92.PubMedCrossRefGoogle Scholar
  137. 137.
    Biesecker BB, Ishibe N, Hadley DW, et al. Psychosocial factors predicting BRCA1/BRCA2 testing decisions in members of hereditary breast and ovarian cancer families. Am J Med Genet 2000;93:257–63.PubMedCrossRefGoogle Scholar
  138. 138.
    Botkin JR, Smith KR, Croyle RT, et al. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A 2003;118:201–9.CrossRefGoogle Scholar
  139. 139.
    Schneider KA. Genetic counseling for BRCA1/BRCA2 testing. Genet Test 1997;1:91–8.PubMedCrossRefGoogle Scholar
  140. 140.
    Armstrong K, Weber B, FitzGerald G, et al. Life insurance and breast cancer risk assessment: adverse selection, genetic testing decisions, and discrimination. Am J Med Genet A 2003;120:359–64.CrossRefGoogle Scholar
  141. 141.
    Matloff ET, Shappell H, Brierley K, Bernhardt BA, McKinnon W, Peshkin BN. What would you do? Specialists’ perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination. J Clin Oncol 2000;18:2484–92.PubMedGoogle Scholar
  142. 142.
    Hudson KL. Prohibiting genetic discrimination. N Engl J Med 2007;356:2021–3.PubMedCrossRefGoogle Scholar
  143. 143.
    Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol 1996;14:1730–6; 0072.Google Scholar
  144. 144.
    Berry DA, Iversen ES Jr., Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002;20:2701–12.PubMedCrossRefGoogle Scholar
  145. 145.
    Brekelmans CT, Seynaeve C, Bartels CC, et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 2001;19:924–30.PubMedGoogle Scholar
  146. 146.
    Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004;351:427–37.PubMedCrossRefGoogle Scholar
  147. 147.
    Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002;20:1260–8.PubMedCrossRefGoogle Scholar
  148. 148.
    Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004;292:1317–25.PubMedCrossRefGoogle Scholar
  149. 149.
    Hackshaw AK, Paul EA. Breast self-examination and death from breast cancer: a meta-analysis. Br J Cancer 2003;88:1047–53.PubMedCrossRefGoogle Scholar
  150. 150.
    Tilanus-Linthorst MM, Obdeijn IM, Bartels KC, de Koning HJ, Oudkerk M. First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat 2000;63:53–60.PubMedCrossRefGoogle Scholar
  151. 151.
    Ziv E, Shepherd J, Smith-Bindman R, Kerlikowske K. Mammographic breast density and family history of breast cancer. J Natl Cancer Inst 2003;95:556–8.PubMedCrossRefGoogle Scholar
  152. 152.
    Buist DS, Porter PL, Lehman C, Taplin SH, White E. Factors contributing to mammography failure in women aged 40–49 years. J Natl Cancer Inst 2004;96:1432–40.PubMedCrossRefGoogle Scholar
  153. 153.
    Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V. Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA 1996;276:33–8.PubMedCrossRefGoogle Scholar
  154. 154.
    Collett K, Stefansson IM, Eide J, et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 2005;14:1108–12.PubMedCrossRefGoogle Scholar
  155. 155.
    Pisano ED, Gatsonis C, Hendrick E, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 2005;353:1773–83.PubMedCrossRefGoogle Scholar
  156. 156.
    Ronckers CM, Erdmann CA, Land CE. Radiation and breast cancer: a review of current evidence. Breast Cancer Res 2005;7:21–32.PubMedCrossRefGoogle Scholar
  157. 157.
    Andrieu N, Easton DF, Chang-Claude J, et al. Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators’ Group. J Clin Oncol 2006;24:3361–6.PubMedCrossRefGoogle Scholar
  158. 158.
    Kuhl CK, Schmutzler RK, Leutner CC, et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 2000;215:267–79.PubMedGoogle Scholar
  159. 159.
    Warner E, Plewes DB, Shumak RS, et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 2001;19:3524–31.PubMedGoogle Scholar
  160. 160.
    Podo F, Sardanelli F, Canese R, et al. The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res 2002;21:115–24.PubMedGoogle Scholar
  161. 161.
    Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005;365:1769–78.PubMedCrossRefGoogle Scholar
  162. 162.
    Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005;23:8469–76.PubMedCrossRefGoogle Scholar
  163. 163.
    Stoutjesdijk MJ, Boetes C, Jager GJ, et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001;93:1095–102.PubMedCrossRefGoogle Scholar
  164. 164.
    Morris EA, Liberman L, Ballon DJ, et al. MRI of occult breast carcinoma in a high-risk population. AJR Am J Roentgenol 2003;181:619–26.PubMedGoogle Scholar
  165. 165.
    Sardanelli F, Podo F. Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection? Eur Radiol 2007;17:873–87.PubMedCrossRefGoogle Scholar
  166. 166.
    Morakkabati-Spitz N, Leutner C, Schild H, Traeber F, Kuhl C. Diagnostic usefulness of segmental and linear enhancement in dynamic breast MRI. Eur Radiol 2005;15: 2010–7.PubMedCrossRefGoogle Scholar
  167. 167.
    Kuhl CK, Schrading S, Bieling HB, et al. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet 2007;370:485–92.PubMedCrossRefGoogle Scholar
  168. 168.
    Robson M, Offit K. Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med 2007;357:154–62.PubMedCrossRefGoogle Scholar
  169. 169.
    Robson ME, Offit K. Breast MRI for women with hereditary cancer risk. JAMA 2004;292:1368–70.PubMedCrossRefGoogle Scholar
  170. 170.
    Lehman CD, Blume JD, Weatherall P, et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 2005;103:1898–905.PubMedCrossRefGoogle Scholar
  171. 171.
    Lord SJ, Irwig L, Simes RJ. When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials? Ann Intern Med 2006;144:850–5.PubMedGoogle Scholar
  172. 172.
    Hermsen BB, Olivier RI, Verheijen RH, et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 2007;96:1335–42.PubMedGoogle Scholar
  173. 173.
    Olivier RI, Lubsen-Brandsma MA, Verhoef S, van Beurden M. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 2006;100:20–6.PubMedCrossRefGoogle Scholar
  174. 174.
    Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77–84.PubMedCrossRefGoogle Scholar
  175. 175.
    Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001;93:1633–7.PubMedCrossRefGoogle Scholar
  176. 176.
    Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:159–64.PubMedCrossRefGoogle Scholar
  177. 177.
    Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004;22:1055–62.PubMedCrossRefGoogle Scholar
  178. 178.
    Herrinton LJ, Barlow WE, Yu O, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 2005;23:4275–86.PubMedCrossRefGoogle Scholar
  179. 179.
    Pennisi VR, Capozzi A. Subcutaneous mastectomy data: a final statistical analysis of 1500 patients. Aesthetic Plast Surg 1989;13:15–21.PubMedCrossRefGoogle Scholar
  180. 180.
    Hartmann LC, Degnim A, Schaid DJ. Prophylactic mastectomy for BRCA1/2 carriers: progress and more questions. J Clin Oncol 2004;22:981–3.PubMedCrossRefGoogle Scholar
  181. 181.
    Guillem JG, Wood WC, Moley JF, et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 2006;24:4642–60.PubMedCrossRefGoogle Scholar
  182. 182.
    Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006;296:185–92.PubMedCrossRefGoogle Scholar
  183. 183.
    Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609–15.PubMedCrossRefGoogle Scholar
  184. 184.
    Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616–22.PubMedCrossRefGoogle Scholar
  185. 185.
    Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005;23:7491–6.PubMedCrossRefGoogle Scholar
  186. 186.
    Domchek SM, Friebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006;7:223–9.PubMedCrossRefGoogle Scholar
  187. 187.
    Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol 2005;97:457–67.PubMedCrossRefGoogle Scholar
  188. 188.
    Rebbeck TR, Friebel T, Wagner T, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005;23:7804–10.PubMedCrossRefGoogle Scholar
  189. 189.
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–88.PubMedCrossRefGoogle Scholar
  190. 190.
    King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001;286:2251–6.PubMedCrossRefGoogle Scholar
  191. 191.
    Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000;356:1876–81.PubMedCrossRefGoogle Scholar
  192. 192.
    Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006;24:2437–43.PubMedCrossRefGoogle Scholar
  193. 193.
    Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 2006;118:2281–4.PubMedCrossRefGoogle Scholar
  194. 194.
    Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22:2328–35.PubMedCrossRefGoogle Scholar
  195. 195.
    Foulkes WD, Goffin J, Brunet JS, Begin LR, Wong N, Chappuis PO. Tamoxifen may be an effective adjuvant treatment for BRCA1-related breast cancer irrespective of estrogen receptor status. J Natl Cancer Inst 2002;94:1504–6.PubMedCrossRefGoogle Scholar
  196. 196.
    Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727–41.PubMedCrossRefGoogle Scholar
  197. 197.
    Premkumar A, Venzon DJ, Avila N, et al. Gynecologic and hormonal effects of raloxifene in premenopausal women. Fertil Steril 2007;88:1637–1644.PubMedCrossRefGoogle Scholar
  198. 198.
    Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998;339:424–8.PubMedCrossRefGoogle Scholar
  199. 199.
    McLaughlin JR, Risch HA, Lubinski J, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 2007;8:26–34.PubMedCrossRefGoogle Scholar
  200. 200.
    Modan B, Hartge P, Hirsh-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:235–40.PubMedCrossRefGoogle Scholar
  201. 201.
    Whittemore AS, Balise RR, Pharoah PD, et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 2004;91:1911–5.PubMedCrossRefGoogle Scholar
  202. 202.
    Haile RW, Thomas DC, McGuire V, et al. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev 2006;15:1863–70.PubMedCrossRefGoogle Scholar
  203. 203.
    Narod SA, Dube MP, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002;94:1773–9.PubMedCrossRefGoogle Scholar
  204. 204.
    Brohet RM, Goldgar DE, Easton DF, et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 2007;25:3831–6.PubMedCrossRefGoogle Scholar
  205. 205.
    Arason A, Barkardottir RB, Egilsson V. Linkage analysis of chromosome 17q markers and breast-ovarian cancer in Icelandic families, and possible relationship to prostatic cancer. Am J Hum Genet 1993;52:711–7.PubMedGoogle Scholar
  206. 206.
    Anderson DE, Badzioch MD. Familial breast cancer risks. Effects of prostate and other cancers. Cancer 1993;72:114–9.PubMedCrossRefGoogle Scholar
  207. 207.
    Nelson CL, Sellers TA, Rich SS, Potter JD, McGovern PG, Kushi LH. Familial clustering of colon, breast, uterine, and ovarian cancers as assessed by family history. Genet Epidemiol 1993;10:235–44.PubMedCrossRefGoogle Scholar
  208. 208.
    Foulkes WD, Metcalfe K, Hanna W, et al. Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer 2003;98:1569–77.PubMedCrossRefGoogle Scholar
  209. 209.
    Foulkes WD. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer 2006;5:135–42.PubMedCrossRefGoogle Scholar
  210. 210.
    Beiner ME, Finch A, Rosen B, et al. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol 2007;104:7–10.PubMedCrossRefGoogle Scholar
  211. 211.
    Lakhani SR, Gusterson BA, Jacquemier J, et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000;6:782–9.PubMedGoogle Scholar
  212. 212.
    Armes JE, Egan AJ, Southey MC, et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 1998;83:2335–45.PubMedCrossRefGoogle Scholar
  213. 213.
    Marcus JN, Watson P, Page DL, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996;77:697–709.PubMedCrossRefGoogle Scholar
  214. 214.
    Marcus JN, Watson P, Page DL, et al. BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Res Treat 1997;44:275–7.PubMedCrossRefGoogle Scholar
  215. 215.
    Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998;90:1138–45.PubMedCrossRefGoogle Scholar
  216. 216.
    Hoogerbrugge N, Bult P, de Widt-Levert LM, et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 2003;21:41–5.PubMedCrossRefGoogle Scholar
  217. 217.
    Kauff ND, Brogi E, Scheuer L, et al. Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer 2003;97:1601–8.PubMedCrossRefGoogle Scholar
  218. 218.
    Chappuis PO, Donato E, Goffin JR, et al. Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. Ann Oncol 2005;16:735–42.PubMedCrossRefGoogle Scholar
  219. 219.
    Chappuis PO, Kapusta L, Begin LR, et al. Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol 2000;18:4045–52.PubMedGoogle Scholar
  220. 220.
    Lynch BJ, Holden JA, Buys SS, Neuhausen SL, Gaffney DK. Pathobiologic characteristics of hereditary breast cancer. Hum Pathol 1998;29:1140–4.PubMedCrossRefGoogle Scholar
  221. 221.
    Quenneville LA, Phillips KA, Ozcelik H, et al. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. Cancer 2002;95:2068–75.PubMedCrossRefGoogle Scholar
  222. 222.
    Goffin JR, Chappuis PO, Begin LR, et al. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer 2003;97:527–36.PubMedCrossRefGoogle Scholar
  223. 223.
    Honrado E, Benitez J, Palacios J. Histopathology of BRCA1- and BRCA2-associated breast cancer. Crit Rev Oncol Hematol 2006;59:27–39.PubMedCrossRefGoogle Scholar
  224. 224.
    Goffin JR, Straume O, Chappuis PO, et al. Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer. Br J Cancer 2003;89:1031–4.PubMedCrossRefGoogle Scholar
  225. 225.
    Grushko TA, Dignam JJ, Das S, et al. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res 2004;10:499–507.PubMedCrossRefGoogle Scholar
  226. 226.
    Adem C, Soderberg CL, Hafner K, et al. ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers. Genes Chromosomes Cancer 2004;41:1–11.PubMedCrossRefGoogle Scholar
  227. 227.
    Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310–8.PubMedCrossRefGoogle Scholar
  228. 228.
    Palacios J, Honrado E, Osorio A, et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 2003;9:3606–14.PubMedGoogle Scholar
  229. 229.
    Eerola H, Heikkila P, Tamminen A, Aittomaki K, Blomqvist C, Nevanlinna H. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 2005;7:R93–100.PubMedCrossRefGoogle Scholar
  230. 230.
    Osin P, Gusterson BA, Philp E, et al. Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers. Eur J Cancer 1998;34:1683–6.PubMedCrossRefGoogle Scholar
  231. 231.
    Eisinger F, Nogues C, Guinebretiere JM, et al. Novel indications for BRCA1 screening using individual clinical and morphological features. Int J Cancer 1999;84:263–7.PubMedCrossRefGoogle Scholar
  232. 232.
    Noguchi S, Kasugai T, Miki Y, Fukutomi T, Emi M, Nomizu T. Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women. Cancer 1999;85:2200–5.PubMedCrossRefGoogle Scholar
  233. 233.
    Robson ME, Chappuis PO, Satagopan J, et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004;6:R8-R17.PubMedCrossRefGoogle Scholar
  234. 234.
    Oldenburg RA, Kroeze-Jansema K, Meijers-Heijboer H, et al. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping. Clin Cancer Res 2006;12:1693–700.PubMedCrossRefGoogle Scholar
  235. 235.
    Foulkes WD, Metcalfe K, Sun P, et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 2004;10:2029–34.PubMedCrossRefGoogle Scholar
  236. 236.
    Grushko TA, Blackwood MA, Schumm PL, et al. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res 2002;62:1481–8.PubMedGoogle Scholar
  237. 237.
    Johannsson OT, Idvall I, Anderson C, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997;33:362–71.PubMedCrossRefGoogle Scholar
  238. 238.
    Stark GR. Regulation and mechanisms of mammalian gene amplification. Adv Cancer Res 1993;61:87–113.PubMedCrossRefGoogle Scholar
  239. 239.
    Honrado E, Osorio A, Palacios J, Benitez J. Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. Oncogene 2006;25:5837–45.PubMedCrossRefGoogle Scholar
  240. 240.
    Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001;344:539–48.PubMedCrossRefGoogle Scholar
  241. 241.
    Vaziri SA, Krumroy LM, Elson P, et al. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res 2001;7:1937–45.PubMedGoogle Scholar
  242. 242.
    Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005;11:5175–80.PubMedCrossRefGoogle Scholar
  243. 243.
    Palacios J, Honrado E, Osorio A, Diez O, Rivas C, Benitez J. Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2004;96:712–4; author reply 4.PubMedCrossRefGoogle Scholar
  244. 244.
    Signoretti S, Di Marcotullio L, Richardson A, et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 2002;110:633–41.PubMedGoogle Scholar
  245. 245.
    Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:1233–41.PubMedCrossRefGoogle Scholar
  246. 246.
    Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;347:1227–32.PubMedCrossRefGoogle Scholar
  247. 247.
    Eccles D, Simmonds P, Goddard J, et al. Familial breast cancer: an investigation into the outcome of treatment for early stage disease. Fam Cancer 2001;1:65–72.PubMedCrossRefGoogle Scholar
  248. 248.
    Robson M, Svahn T, McCormick B, et al. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer 2005;103:44–51.PubMedCrossRefGoogle Scholar
  249. 249.
    Seynaeve C, Verhoog LC, van de Bosch LM, et al. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer 2004;40:1150–8.PubMedCrossRefGoogle Scholar
  250. 250.
    Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003;63:6221–8.PubMedGoogle Scholar
  251. 251.
    Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004;96:1659–68.PubMedCrossRefGoogle Scholar
  252. 252.
    Chappuis PO, Goffin J, Wong N, et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 2002;39:608–10.PubMedCrossRefGoogle Scholar
  253. 253.
    Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678–85.PubMedCrossRefGoogle Scholar
  254. 254.
    Rubinstein WS. Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics. Fam Cancer 2007.Google Scholar
  255. 255.
    Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917–21.PubMedCrossRefGoogle Scholar
  256. 256.
    Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913–7.PubMedCrossRefGoogle Scholar
  257. 257.
    Helleday T, Bryant HE, Schultz N. Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 2005;4:1176–8.PubMedCrossRefGoogle Scholar
  258. 258.
    Szabo G, Bahrle S, Stumpf N, et al. Poly(ADP-Ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. Circ Res 2002;90:100–6.PubMedCrossRefGoogle Scholar
  259. 259.
    Alano CC, Kauppinen TM, Valls AV, Swanson RA. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci USA 2006;103:9685–90.PubMedCrossRefGoogle Scholar
  260. 260.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–82.PubMedCrossRefGoogle Scholar
  261. 261.
    Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol 1999;17:3396–402.PubMedGoogle Scholar
  262. 262.
    Rennert G, Bisland-Naggan S, Barnett-Griness O, et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007;357:115–23.PubMedCrossRefGoogle Scholar
  263. 263.
    Li FP, Fraumeni JF Jr. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 1969;43:1365–73.PubMedGoogle Scholar
  264. 264.
    Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233–8.PubMedCrossRefGoogle Scholar
  265. 265.
    Malkin D. p53 and the Li-Fraumeni syndrome. Cancer Genet Cytogenet 1993;66:83–92.PubMedCrossRefGoogle Scholar
  266. 266.
    Easton D, Ford D, Peto J. Inherited susceptibility to breast cancer. Cancer Surv 1993;18:95–113.PubMedGoogle Scholar
  267. 267.
    Hisada M, Garber JE, Fung CY, Fraumeni JF Jr., Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998;90:606–11.PubMedCrossRefGoogle Scholar
  268. 268.
    Lloyd KM II, Dennis M. Cowden’s disease. A possible new symptom complex with multiple system involvement. Ann Intern Med 1963;58:136–42.PubMedGoogle Scholar
  269. 269.
    Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943–7.PubMedCrossRefGoogle Scholar
  270. 270.
    Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356–62.PubMedCrossRefGoogle Scholar
  271. 271.
    Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997;57:2124–9.PubMedGoogle Scholar
  272. 272.
    Lopiccolo J, Ballas MS, Dennis PA. PTEN hamartomatous tumor syndromes (PHTS): rare syndromes with great relevance to common cancers and targeted drug development. Crit Rev Oncol Hematol 2007;63:203–14.PubMedCrossRefGoogle Scholar
  273. 273.
    Longy M, Lacombe D. Cowden disease. Report of a family and review. Ann Genet 1996;39:35–42.PubMedGoogle Scholar
  274. 274.
    Schrager CA, Schneider D, Gruener AC, Tsou HC, Peacocke M. Clinical and pathological features of breast disease in Cowden’s syndrome: an underrecognized syndrome with an increased risk of breast cancer. Hum Pathol 1998;29:47–53.PubMedCrossRefGoogle Scholar
  275. 275.
    Hemminki A. The molecular basis and clinical aspects of Peutz-Jeghers syndrome. Cell Mol Life Sci 1999;55:735–50.PubMedCrossRefGoogle Scholar
  276. 276.
    Jenne DE, Reimann H, Nezu J, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998;18:38–43.PubMedCrossRefGoogle Scholar
  277. 277.
    Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 2006;12:3209–15.PubMedCrossRefGoogle Scholar
  278. 278.
    Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 1987;316:1289–94.PubMedCrossRefGoogle Scholar
  279. 279.
    Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991;325:1831–6.PubMedCrossRefGoogle Scholar
  280. 280.
    Vorechovsky I, Luo L, Lindblom A, et al. ATM mutations in cancer families. Cancer Res 1996;56:4130–3.PubMedGoogle Scholar
  281. 281.
    FitzGerald MG, Bean JM, Hegde SR, et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 1997;15:307–10.PubMedCrossRefGoogle Scholar
  282. 282.
    Wooster R, Ford D, Mangion J, et al. Absence of linkage to the ataxia telangiectasia locus in familial breast cancer. Hum Genet 1993;92:91–4.PubMedCrossRefGoogle Scholar
  283. 283.
    Athma P, Rappaport R, Swift M. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 1996;92:130–4.PubMedCrossRefGoogle Scholar
  284. 284.
    Chen J, Birkholtz GG, Lindblom P, Rubio C, Lindblom A. The role of ataxia-telangiectasia heterozygotes in familial breast cancer. Cancer Res 1998;58:1376–9.PubMedGoogle Scholar
  285. 285.
    Easton DF. Cancer risks in A-T heterozygotes. Int J Radiat Biol 1994;66:S177–82.PubMedCrossRefGoogle Scholar
  286. 286.
    Cortessis V, Ingles S, Millikan R, et al. Linkage analysis of DRD2, a marker linked to the ataxia-telangiectasia gene, in 64 families with premenopausal bilateral breast cancer. Cancer Res 1993;53:5083–6.PubMedGoogle Scholar
  287. 287.
    Nevanlinna H, Bartek J. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 2006;25:5912–9.PubMedCrossRefGoogle Scholar
  288. 288.
    Bell DW, Kim SH, Godwin AK, et al. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer 2007;121:2661–7.PubMedCrossRefGoogle Scholar
  289. 289.
    Schmidt MK, Tollenaar RA, de Kemp SR, et al. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol 2007;25:64–9.PubMedCrossRefGoogle Scholar
  290. 290.
    Dannan GA, Porubek DJ, Nelson SD, Waxman DJ, Guengerich FP. 17 beta-estradiol 2- and 4-hydroxylation catalyzed by rat hepatic cytochrome P-450: roles of individual forms, inductive effects, developmental patterns, and alterations by gonadectomy and hormone replacement. Endocrinology 1986;118:1952–60.PubMedCrossRefGoogle Scholar
  291. 291.
    Forrester LM, Hayes JD, Millis R, et al. Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue. Carcinogenesis 1990;11:2163–70.PubMedCrossRefGoogle Scholar
  292. 292.
    Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997;6:733–43.PubMedGoogle Scholar
  293. 293.
    Rebbeck TR, Rogatko A, Viana MA. Evaluation of genotype data in clinical risk assessment: methods and application to BRCA1, BRCA2, and N-acetyl transferase-2 genotypes in breast cancer. Genet Test 1997;1:157–64.PubMedCrossRefGoogle Scholar
  294. 294.
    van ‘t Veer LJ, Dai H, van de Vijver MJ, et al. Expression profiling predicts outcome in breast cancer. Breast Cancer Res 2003;5:57–8.PubMedCrossRefGoogle Scholar
  295. 295.
    Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726–34.PubMedCrossRefGoogle Scholar
  296. 296.
    Esteva FJ, Sahin AA, Cristofanilli M, et al. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 2005;11:3315–9.PubMedCrossRefGoogle Scholar
  297. 297.
    Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747–52.PubMedCrossRefGoogle Scholar
  298. 298.
    Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869–74.PubMedCrossRefGoogle Scholar
  299. 299.
    Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418–23.PubMedCrossRefGoogle Scholar
  300. 300.
    Perreard L, Fan C, Quackenbush JF, et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res 2006;8:R23.PubMedCrossRefGoogle Scholar
  301. 301.
    Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492–502.PubMedCrossRefGoogle Scholar
  302. 302.
    Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006;7:96.PubMedCrossRefGoogle Scholar
  303. 303.
    van ’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530–6.CrossRefGoogle Scholar
  304. 304.
    van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999–2009.PubMedCrossRefGoogle Scholar
  305. 305.
    Buyse M, Loi S, van’t Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183–92.PubMedCrossRefGoogle Scholar
  306. 306.
    Morris SR, Carey LA. Gene expression profiling in breast cancer. Curr Opin Oncol 2007;19:547–51.PubMedCrossRefGoogle Scholar
  307. 307.
    Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817–26.PubMedCrossRefGoogle Scholar
  308. 308.
    Wessels LF, van Welsem T, Hart AA, van’t Veer LJ, Reinders MJ, Nederlof PM. Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res 2002;62:7110–7.PubMedGoogle Scholar
  309. 309.
    Jonsson G, Naylor TL, Vallon-Christersson J, et al. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res 2005;65:7612–21.PubMedGoogle Scholar
  310. 310.
    Barcenas CH, Hosain GM, Arun B, Zong J, Zhou X, Chen J, Cortada JM, Mills GB, Tomlinson GE, Miller AR, Strong LC, Amos CI. Assessing BRCA carrier probabilities in extended families. J Clin Oncol. 2006 Jan 20;24(3):354–60.PubMedGoogle Scholar
  311. 311.
    Evans DG, Lalloo F, Wallace A, Rahman N. Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. J Med Genet. 2005 Jul;42(7):e39.PubMedGoogle Scholar
  312. 312.
    Euhus DM. Understanding mathematical models for breast cancer risk assessment and counseling. Breast J. 2001 Jul-Aug;7(4):224–32.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Alfredo A. Santillan
    • 1
  • Jeffrey M. Farma
  • Ramona Hagmaier
  • Charles E. Cox
  • Adam I. Riker
  1. 1.Division of Surgical Oncology, Department of Surgery Cancer Therapy and Research CenterUniversity of Texas Health Science Center at San AntonioSan AntonioUSA

Personalised recommendations